NKTR Nektar Therapeutics

31.68
+0.49  (+2%)
Previous Close 31.19
Open 31.22
Price To Book 3.21
Market Cap 5515629261
Shares 174,104,459
Volume 3,747,307
Short Ratio
Av. Daily Volume 1,717,195

NewsSee all news

  1. These 3 Falling Knives Are Expected to Outperform
  2. Analysts believe the stock market will set a record soon and these names are going to lead the way
  3. GameStop falls while Dave & Buster's and Blue Apron rise
  4. A Look At Nektar Therapeutics's (NASDAQ:NKTR) Exceptional Fundamentals
  5. Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated data February 11, 2019 noted ORR to 48% (13/27) in patients with urothelial carcinoma.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Phase 1/2 commencement of dosing announced September 12, 2017. Initial data presented at ASCO 2018
NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
Bronchiectasis
PDUFA date extended three months to August 29, 2019.
NKTR-181
Lower back pain
Phase 3 data released November 24, 2017. Endpoints not met.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 1/2 initial data March 1, 2019 noted ORR 2/11 ( 18%) - maximum tolerated dose has not been reached.
NKTR-262 and NKTR-214 - REVEAL
Solid tumors
Phase 1b initiation announced May 8, 2018.
NKTR-358
Systemic lupus erythematosus (SLE)

Latest News

  1. These 3 Falling Knives Are Expected to Outperform
  2. Analysts believe the stock market will set a record soon and these names are going to lead the way
  3. GameStop falls while Dave & Buster's and Blue Apron rise
  4. A Look At Nektar Therapeutics's (NASDAQ:NKTR) Exceptional Fundamentals
  5. Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
  6. See what the IHS Markit Score report has to say about Nektar Therapeutics.
  7. The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
  8. Here are the typical employee salaries at Twitter, Salesforce, Yelp, Square, Zynga, Dolby and other tech companies
  9. Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
  10. Nektar (NKTR) Down 17.1% Since Last Earnings Report: Can It Rebound?
  11. 3 Stocks That Could Double Your Money
  12. Stock Market News For Mar 7, 2019
  13. Edited Transcript of NKTR earnings conference call or presentation 28-Feb-19 10:00pm GMT
  14. Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference
  15. Biotech Companies Slump Midday With FDA Chief Set to Leave
  16. Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver — What Drives Growth in Today's Competitive Landscape
  17. BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
  18. Nektar Therapeutics Inc (NKTR) Files 10-K for the Fiscal Year Ended on December 31, 2018
  19. Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting